keyword
MENU ▼
Read by QxMD icon Read
search

Ranibizumab

keyword
https://www.readbyqxmd.com/read/27914833/efficacy-of-primary-intravitreal-ranibizumab-for-retinopathy-of-prematurity-in-china
#1
Jing Feng, Jing Qian, Yanrong Jiang, Mingwei Zhao, Jianhong Liang, Hong Yin, Yi Chen, Wenzhen Yu, Xiaoxin Li
No abstract text is available yet for this article.
November 30, 2016: Ophthalmology
https://www.readbyqxmd.com/read/27913869/ranibizumab-for-vascularized-pigment-epithelial-detachment-1-year-anatomic-and-functional-results
#2
Olivier Chevreaud, Hassiba Oubraham, Salomon Y Cohen, Camille Jung, Rocio Blanco-Garavito, Farah Gherdaoui, Eric H Souied
PURPOSE: To assess the anatomical and functional efficacy of ranibizumab on vascularized pigment epithelial detachment (V-PED) secondary to neovascular age-related macular degeneration (nAMD). METHODS: One hundred and nine patients (116 eyes) were retrospectively selected from medical records of 2097 patients who benefited from intravitreal injection between January 2011 and June 2013 in a tertiary-care University-based Department of Ophthalmology. Inclusion criteria were: nAMD, treatment-naive eyes, presence of V-PED higher than 250 μm, intravitreal ranibizumab with a loading phase, followed by a pro-re-nata regimen, and 1-year follow-up...
December 3, 2016: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/27913442/comparison-of-anti-vegf-therapies-on-fibrovascular-pigment-epithelial-detachments-in-age-related-macular-degeneration
#3
Adrian Au, Vishal S Parikh, Rishi P Singh, Justis P Ehlers, Alex Yuan, Aleksandra V Rachitskaya, Jonathan E Sears, Sunil K Srivastava, Peter K Kaiser, Andrew P Schachat, Daniel F Martin, Yasha Modi
BACKGROUND: The aim is to compare the therapeutic effects of three antivascular endothelial growth factor (VEGF) drugs (bevacizumab, aflibercept and ranibizumab) on fibrovascular pigment epithelial detachments (fvPEDs) in age-related macular degeneration (AMD). METHODS: This was a retrospective, comparative, consecutive case series of 88 unique eyes with fvPEDs in neovascular AMD treated with anti-VEGF monotherapy for a minimum of 6 months. All eyes were treatment naive...
December 2, 2016: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/27912913/intravitreal-therapies-for-non-neovascular-age-related-macular-degeneration-with-intraretinal-or-subretinal-fluid
#4
M Cuesta-Lasso, A Vieira-Barros, R Dolz-Marco, M J Roig-Revert, J Badal, L Amselem, M Díaz-Llopis, R Gallego-Pinazo
OBJECTIVE: To evaluate the efficacy of intravitreal therapies in cases of atrophic age-related macular degeneration (AMD) with subretinal or intraretinal fluid. METHODS: A retrospective review was made of the clinical charts of patients diagnosed with atrophic AMD with subretinal or intraretinal fluid. Fundus photographs and spectral-domain optical coherence tomography images were examined, and an analysis was made on the presence of fluid and its density. Neovascularisation was ruled out by fluorescein and/or indocyanine green angiography...
November 29, 2016: Archivos de la Sociedad Española de Oftalmología
https://www.readbyqxmd.com/read/27911446/treatment-patterns-of-ranibizumab-intravitreal-injection-and-dexamethasone-intravitreal-implant-for-retinal-vein-occlusion-in-the-usa
#5
S Nghiem-Buffet, S Baillif, S Regnier, A Skelly, N Yu, A Sodi
PurposeRanibizumab, an anti-vascular endothelial growth factor, and dexamethasone, a corticosteroid, have been shown to be effective in treating macular oedema secondary to retinal vein occlusion (RVO) (central RVO (CRVO) and branch RVO (BRVO)). Their real-world usage, however, has yet to be compared. We therefore evaluated ophthalmology visits for both drugs using US patient-level data.MethodsThe IMS Health Real-World Data Medical Claims database was used to identify treatment-naive patients receiving ranibizumab intravitreal injections or dexamethasone intravitreal implants between June 2010 and February 2014 who had 12 months of follow-up data...
December 2, 2016: Eye
https://www.readbyqxmd.com/read/27911420/-role-of-immunological-factors-in-the-development-of-myopic-choroidal-neovascularization
#6
A G Shchuko, N V Zaitseva, T N Yur'eva, E R Chernykh, I M Mikhalevich, A V Grigor'eva
AIM: To study the concentration of cytokines in the aqueous humor of the anterior chamber in patients with myopic choroidal neovascularization (mCNV) and to compare the results to their ophthalmic status. MATERIAL AND METHODS: A total of 19 patients (19 eyes) with mCNV treated with intravitreal ranibizumab were included in the study. The control group consisted of 15 patients (15 eyes) with myopia who had cataract surgery. Age, sex, and refractive error distribution were similar to that in the study group...
2016: Vestnik Oftalmologii
https://www.readbyqxmd.com/read/27905340/effect-of-prophylactic-intraocular-pressure-lowering-medication-brinzolamide-on-intraocular-pressure-after-ranibizumab-intravitreal-injection-a-case-control-study
#7
Shuang Song, Xiao-Bing Yu, Hong Dai
PURPOSE: To observe the effect of prophylactic intraocular pressure (IOP)-lowering medication (brinzolamide) on IOP after ranibizumab intravitreal injections (IVIs). MATERIALS AND METHODS: This prospective case-control study included 352 eyes from 352 patients (1 eye per patient) who were treated with ranibizumab intravitreal injection and divided randomly into two groups. Two hundred and three patients in control group only received the ranibizumab IVI, but 149 patients in case group received one drop of prophylactic intraocular brinzolamide preinjection...
October 2016: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/27901006/intravitreal-ranibizumab-for-aggressive-posterior-retinopathy-of-prematurity
#8
Xiu-Juan Li, Xiao-Peng Yang, Shuang Sun, Xiao-Bei Lyu, Heng Jia
No abstract text is available yet for this article.
2016: Chinese Medical Journal
https://www.readbyqxmd.com/read/27898414/outcomes-after-a-1-year-treatment-with-ranibizumab-for-diabetic-macular-edema-in-a-clinical-setting
#9
Linda Hrarat, Franck Fajnkuchen, Marouane Boubaya, Vincent Lévy, Valérie Sarda, Typhaine Grenet, Sylvia Nghiem-Buffet, Gilles Chaine, Audrey Giocanti-Auregan
PURPOSE: The aim of this study was to assess the efficacy and safety of ranibizumab in patients with diabetic macular edema (DME). METHODS: We conducted a retrospective analysis of consecutive patients with vision loss due to DME who were treated with ranibizumab. All patients received a loading dose of 3 monthly injections followed by re-treatments on an as-needed basis. The primary endpoint was the change in best-corrected visual acuity (BCVA) at 12 months. Secondary endpoints were the change in central retinal thickness (CRT) and the number of intravitreal injections (IVI) at 12 months...
November 30, 2016: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/27892746/choroidal-neovascularization-associated-with-multiple-evanescent-white-dot-syndrome-treated-with-intravitreal-ranibizumab
#10
Maurizio Battaglia Parodi, Pierluigi Iacono, Ilaria Zucchiatti, Francesco Bandello
PURPOSE: To describe the clinical outcomes of intravitreal ranibizumab treatment for subfoveal choroidal neovascularization (CNV) associated with multiple evanescent white dot syndrome (MEWDS). METHODS: This is a prospective, interventional, case series. All recruited patients underwent a baseline intravitreal ranibizumab injection and were monitored monthly over a 12-month follow-up, following a pro-re-nata regimen. RESULTS: Four patients (four eyes) were included in the study...
November 28, 2016: Ocular Immunology and Inflammation
https://www.readbyqxmd.com/read/27890437/trends-of-anti-vascular-endothelial-growth-factor-use-in-ophthalmology-among-privately-insured-and-medicare-advantage-patients
#11
Ravi Parikh, Joseph S Ross, Lindsey R Sangaralingham, Ron A Adelman, Nilay D Shah, Andrew J Barkmeier
PURPOSE: To characterize the first 10 years of intravitreal anti-vascular endothelial growth factor (VEGF) medication use for ophthalmic disease, including bevacizumab, ranibizumab, and aflibercept. DESIGN: A retrospective cohort study using administrative claims data from January 1, 2006 to December 31, 2015. SUBJECTS: Total of 124 835 patients 18 years of age or over in the United States. METHODS: OptumLabs Data Warehouse, which includes administrative claims data for over 100 million commercially insured and Medicare Advantage individuals, was used to identify patients receiving intravitreal anti-VEGF injections based on Current Procedural Terminology codes...
November 24, 2016: Ophthalmology
https://www.readbyqxmd.com/read/27885338/effects-of-intravitreal-ranibizumab-injection-on-chinese-patients-with-wet-age-related-macular-degeneration-5-year-follow-up-results
#12
Yingyi Lu, Jianfeng Huang, Jing Zhao, Xiaobing Yu, Li Long, Hong Dai
Purpose. To observe the effect of intravitreal ranibizumab injection on wet age-related macular degeneration (wAMD) over 5 years in Chinese patients. Methods. Thirty-seven patients who were diagnosed with wAMD in our hospital from June 2007 to June 2014 were retrospectively reviewed. The PRN regimen and the treatment and extend regimen were applied. Best corrected visual acuity (BCVA), number of ranibizumab injections, and changes in the choroidal neovascularization (CNV) lesion over 5 years were analyzed. Results...
2016: Journal of Ophthalmology
https://www.readbyqxmd.com/read/27881184/stereotactic-radiotherapy-for-wet-age-related-macular-degeneration-star-study-protocol-for-a-randomised-controlled-clinical-trial
#13
James E Neffendorf, Riti Desai, Yanzhong Wang, Joanna Kelly, Caroline Murphy, Barnaby C Reeves, Usha Chakravarthy, Sarah Wordsworth, Cornelius Lewis, Janet Peacock, Shahir Uddin, Joe M O'Sullivan, Timothy L Jackson
BACKGROUND: The standard of care for neovascular age-related macular degeneration (nAMD) involves ongoing intravitreal injections of anti-angiogenic drugs targeting vascular endothelial growth factor (VEGF). The most commonly used anti-VEGF drugs are ranibizumab, bevacizumab and aflibercept. The main objective of the STAR trial is to determine if stereotactic radiotherapy can reduce the number of anti-VEGF injections that patients with nAMD require. METHODS/DESIGN: STAR is a multicentre, double-masked, randomised, sham-controlled clinical trial...
November 24, 2016: Trials
https://www.readbyqxmd.com/read/27878592/high-frequency-aflibercept-injections-in-persistent-neovascular-age-related-macular-degeneration
#14
Ilkay Kilic Muftuoglu, Frank F Tsai, Raouf Gaber, Mostafa Alam, Amit Meshi, William R Freeman
PURPOSE: To report the 1-year outcomes of every-4-weeks (Q4W) as-needed aflibercept treatment in resistant neovascular age-related macular degeneration (nAMD) patients who had been treated and failed prior bevacizumab or ranibizumab injections, and who also responded poorly to every-8-weeks (Q8W) aflibercept treatment. METHODS: Forty-three eyes of 39 patients with persistent nAMD despite monthly bevacizumab and/or ranibizumab injections and who were switched to Q8W 2-mg aflibercept injections, but showed persistence of fluid were included...
November 23, 2016: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/27865764/phase-2a-randomized-clinical-trial-safety-and-post-hoc-analysis-of-subretinal-raav-sflt-1-for-wet-age-related-macular-degeneration
#15
Ian J Constable, Cora M Pierce, Chooi-May Lai, Aaron L Magno, Mariapia A Degli-Esposti, Martyn A French, Ian L McAllister, Steve Butler, Samuel B Barone, Steven D Schwartz, Mark S Blumenkranz, Elizabeth P Rakoczy
BACKGROUND: We present the results of a Phase 2a randomized controlled trial investigating the safety, and secondary endpoints of subretinal rAAV.sFLT-1 gene therapy in patients with active wet age-related macular degeneration (wAMD). METHODS: All patients (n=32), (ClinicalTrials.gov; NCT01494805), received ranibizumab injections at baseline and week 4, and thereafter according to prespecified criteria. Patients in the gene therapy group (n=21) received rAAV.sFLT-1 (1×10(11)vg)...
November 10, 2016: EBioMedicine
https://www.readbyqxmd.com/read/27865689/retinal-oximetry-during-treatment-of-retinal-vein-occlusion-by-ranibizumab-in-patients-with-high-blood-pressure-and-dyslipidemia
#16
C Keilani, A Halalchi, D Wakpi Djeugue, A Regis, S Abada
INTRODUCTION: In the present study, we examined retinal vascular oxygen saturation in patients with retinal vein occlusion (RVO), high blood pressure (HBP) and dyslipidemia, before and during intravitreal vascular endothelial growth factor (VEGF) injection (ranibizumab). METHODS: We retrospectively reviewed the medical records of six patients with visual acuity (VA) reduced by macular edema (ME) secondary to RVO with HBP and dyslipidemia, who underwent intravitreal anti-VEGF injection between October 2014 and February 2015 in the department of ophthalmology of François-Quesnay Hospital at Mantes-la-Jolie (France)...
November 16, 2016: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/27863845/macular-atrophy-in-neovascular-age-related-macular-degeneration-with-monthly-versus-treat-and-extend-ranibizumab-findings-from-the-trex-amd-trial
#17
Nizar S Abdelfattah, Mayss Al-Sheikh, Sean Pitetta, Ahmed Mousa, SriniVas R Sadda, Charles C Wykoff
PURPOSE: To compare the enlargement rate of macular atrophy (ERMA) in eyes treated with ranibizumab monthly or using a treat-and-extend (TREX) regimen for neovascular age-related macular degeneration (AMD) or fellow control eyes, as well as analyze risk factors for macular atrophy (MA) development and progression. DESIGN: Eighteen-month, multicenter, randomized, controlled clinical trial. PARTICIPANTS: Sixty patients with treatment-naïve neovascular AMD in 1 eye randomized 1:2 to monthly or TREX ranibizumab...
November 15, 2016: Ophthalmology
https://www.readbyqxmd.com/read/27860530/retinal-nerve-fiber-layer-thickness-changes-in-age-related-macular-degeneration-treated-with-multiple-intravitreal-ranibizumab
#18
Elvan Alper Sengul, Ozgur Artunay, Esra Turkseven Kumral, Melda Yenerel, Rifat Rasier, Alev Kockar, Erdal Yuzbasioglu
PURPOSE: The objective of this study was to investigate the effect of multiple intravitreal ranibizumab (IVR) injections on the retinal nerve fiber layer (RNFL) in neovascular age-related macular degeneration (nAMD). METHODS: One hundred sixty-eight eyes of 168 patients with nAMD who received an IVR at least 3 times were included in this prospective interventional case series. The RNFL thickness data on 80 healthy eyes, used as the control group, were obtained. The patients were grouped as follows: 3-10 injections (group 1, 62 eyes, 37%), 10-20 injections (group 2, 62 eyes, 37%), and ≥20 injections (group 3, 44 eyes, 26%)...
November 18, 2016: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27854373/author-s-reply-to-comments-to-ranibizumab-for-persistent-diabetic-macular-edema-after-bevacizumab-treatment
#19
Gabriel Katz
No abstract text is available yet for this article.
October 22, 2016: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/27847638/aflibercept-in-branch-retinal-vein-occlusion-as-second-line-therapy-clinical-outcome-12%C3%A2-months-after-changing-treatment-from-bevacizumab-ranibizumab-a-pilot-study
#20
Magdalena A Wirth, Matthias D Becker, Nicole Graf, Stephan Michels
PURPOSE: To evaluate the effect of aflibercept (as second line therapy) on the clinical outcome in patients with chronic macular edema secondary to branch retinal vein occlusion (BRVO) insufficiently responding to prior treatment with bevacizumab and/or ranibizumab. METHODS: Ten eyes of ten patients (n = 10) with chronic macular edema secondary to BRVO were included in a retrospective analysis. These patients received aflibercept after an insufficient response to treatment with ranibizumab and/- or bevacizumab...
2016: International Journal of Retina and Vitreous
keyword
keyword
1767
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"